Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | PPARG | P37231 | 6/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | PPARA | Q07869 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CPA1 | P15085 | 2/20 | 0.52 |
| ▸ | CPA3 | P15088 | 2/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | CPB1 | P15086 | 1/20 | 0.52 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.52 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7713441 | 0.92 | PPARG (0.71) | CYP1A2PPARGEPHX2PPARAKMT2A | |
| SCHEMBL7713444 | 0.92 | PPARG (0.71) | CYP1A2PPARGEPHX2PPARAKMT2A | |
| Hydrochloric Acid SCHEMBL9239573 | 0.91 | PPARG (0.69) | CYP1A2PPARGEPHX2PPARAKMT2A | |
| SCHEMBL28074267 | 0.88 | CPA1 (0.70) | CYP1A2PPARGEPHX2PPARAKMT2A | |
| SCHEMBL4619329 | 0.88 | PPARG (0.55) | CYP1A2PPARGEPHX2PPARAKMT2A | |
| Hydrochloric Acid SCHEMBL7990559 | 0.87 | PPARG (0.54) | CYP1A2PPARGEPHX2PPARAKMT2A | |
| SCHEMBL29331235 | 0.85 | PPARG (0.49) | CYP1A2PPARGEPHX2PPARAKMT2A | |
| SCHEMBL6712771 | 0.84 | PPARG (0.59) | PPARGPPARASLC6A4 | |
| SCHEMBL8301284 | 0.84 | PPARG (0.48) | CYP1A2PPARGEPHX2PPARAKMT2A | |
| SCHEMBL8384161 | 0.84 | SLC1A1 (0.73) | PPARGEPHX2PPARASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | disclosed |
| CN-1886391-A | Teramic acid and threonine as beta-secretase inhibitors | HOFFMANN LA ROCHE (CH) | 2006-12-27 | — | — | CN | disclosed |
| EP-1689729-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. Hoffmann-La Roche AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005058857-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | disclosed |
| EP-0353211-A1 | New compounds | Aktiebolaget Hässle (SE) | 1990-01-31 | — | — | EP | disclosed |
| US-4870183-A | RENIN INHIBITORS, HYPOTENSIVES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1989-09-26 | — | — | US | disclosed |
| EP-0252727-A1 | Novel amino acid derivatives | Kissei Pharmaceutical Co. Ltd. (JP) | 1988-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | BACE1, PSEN1, BACE2 | CYP1A2 2117/4885PPARG 3310/4885EPHX2 1954/4885 |
| US-20050119329-A1 | Tetronic and tetramic acids | BACE1, PSEN1, BACE2 | CYP1A2 2117/4885PPARG 3310/4885EPHX2 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.